ABC: Co-enrolment CRF NOT required
Achilles tendon pain management (ATM): Co-enrolment CRF NOT required
ARB: Co-enrolment CRF required
Bridging the Age Gap
Cardiac CARE (ISRCTN24439460): Co-enrolment CRF required
CAVA: Co-enrolment CRF NOT required
C-GALL
For any patient undergoing surgery (whether as part of the C-GALL trial or otherwise) a break in Add-Aspirin trial treatment of up to 3 months is acceptable, if deemed appropriate by the treating clinician (and is preferable to stopping treatment altogether). If regular NSAID use is prescribed (for example, as part of medical management in the C-GALL trial), the patient would need to stop Add-Aspirin trial treatment – please see section 5.11 of the protocol (v7.0) for full guidance regarding use of other medications
Chemo-NEAR: Co-enrolment CRF NOT required
ECLIPSE (2016-004424-38)
EFFECT: Co-enrolment CRF required
EndoPREDICT: Co-enrolment CRF required
EPHOS-B (ISRCTN15004993): Co-enrolment CRF required
E-RAPID: Co-enrolment CRF NOT required
eSMART: Co-enrolment CRF required
Patients should be approached for eSMART first. They should only be approached for Add-Aspirin once they have been randomised in eSMART
EUROPAC: Co-enrolment CRF NOT required
FAST-Forward (ISRCTN19906132): Co-enrolment CRF required
HORIZONS: Co-enrolment CRF NOT required
IBIS-II Prevention (ISRCTN37546358): Co-enrolment CRF required
IMPORT-HIGH (ISRCTN47437448): Co-enrolment CRF required
MINT (NCT04276727): Co-enrolment CRF required
MITOCHONDRIAL DNA IN OXALIPLATIN INDUCED NEUROPATHY: Co-enrolment CRF NOT required
OPPORTUNE (ISRCTN26131497): Co-enrolment CRF required
OPTIMA (ISRCTN42400492): Co-enrolment CRF required
ORANGE II (NCT01441856): Co-enrolment CRF NOT required
PALLAS (NCT02513394): Co-enrolment CRF required
PALLET (ISRCTN31243262): Co-enrolment CRF required
PARTNER (2015-002811-13): Co-enrolment CRF required
Please note the PARTNER trial must be notified when patients are co-enrolled to Add-Aspirin
Persephone (ISRCTN52968807): Co-enrolment CRF required
PIONEER (2016-003752-79): Co-enrolment CRF required
PIVOTALBoost
POBRAD-M: Co-enrolment CRF NOT required
POETIC-2 Feasibility: Co-enrolment CRF required
POSNOC (ISRCTN54765244): Co-enrolment CRF required
PQIP: Co-enrolment CRF NOT required
PRINCIPLE (hydroxycholoroquine and azithromycin arms): Co-enrolment CRF required
PROACT (NCT03265574): Co-enrolment CRF required
PROACT End of Study visit must be completed with confirmation that blood samples were processed successfully. Patients should not commence the aspirin run-in before this visit has taken place, but can be consented and registered to Add-Aspirin
PROSPER: Co-enrolment CRF NOT required
RIO (ISRCTN92154110): Co-enrolment CRF required
ROSCO (ISRCTN00430739): Co-enrolment CRF required
SCOT-HEART 2: Co-enrolment CRF required
STAKT: Co-enrolment CRF required
STAKT patients can enter Add-Aspirin provided they have completed their 30 day post-treatment visit (visit 5)
TACT: Co-enrolment CRF NOT required
TARGIT-B: Co-enrolment CRF required
Thrombin Inhibition Preoperatively in Early Breast Cancer (TIP): Co-enrolment CRF required
TRAK-ER: Co-enrolment CRF required
USG PECS vs LIA for breast surgery: Co-enrolment CRF required
VITDALIZE UK: Co-enrolment CRF NOT required